Pseudomonas aeruginosa is an important cause of nosocomial infections, ranking as the foremost pathogen in lower respiratory tract infections, the third most common in surgical wound infections, and the fifth most frequent cause of urinary tract infections.l 1 ] Acylureido-penicillins, some third generation cephalosporins, aminoglycosides, imipenem, and aztreonam are the drugs of choice in the therapy of P. aeruginosa infections, all administered by the parenteral routeP]
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In the first in vitro studies, ciprofloxacin showed a broad antibacterial spectrum of action and, particularly, good efficacy against P. aeruginosa, as evidenced by minimum inhibitory concentrations (MICs) :::;; 0.5 mglL)3.4] Because of its activity, oral administration, low toxicity, and good compliance, ciprofloxacin began to be successfully used in the therapy of many infections caused by P. ' aeruginosa.l 5 ,6] Unfortunately, there have been reports of decreased efficacy of ciprofloxacin against this pathogen: early studies evidenced a rise in MIC values from 0.06 to 0.5 mg/L before treatment to 2 to 8 mg/L during or after therapyP-9] Subsequent researchers confirmed these findings.l10,1l]
We performed this study to evaluate the frequency of ciprofloxacin resistance in nosocomial strains of P. aeruginosa isolated from different body sites of patients in the city of Florence during a 2-year period.
From 1 February 1990 to 31 January 1992 we isolated 505 P. aeruginosa strains: 111 from urine cultures containing ~ 100 000 bacterialml of a single species, 138 from cultures of skin lesions, 51 from blood cultures, and 205 from cultures of bronchial secretions. Both identification and in vitro susceptibility of the isolates were determined by an automated method (VITEK®).
MIC breakpoints for ciprofloxacin were consid- In contrast to other authors, who suggested that ciprofloxacin resistance might emerge only infrequently in isolates from the urine,l9,12] we found more resistant strains in the urinary tract than in the other body sites, probably reflecting inadequate dosage or local risk factors (presence of renal calculi, chronicity of infection, complicated anatomical anomalies, urinary catheters, sequestered infection).l13]
